---
title: An ISHLT consensus statement on strategies to preventÂ and manage hemocompatibility
  related adverse events in patients with a durable, continuous-flow ventricular assist
  device
date: '2024-06-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38878021/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240615180904&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Life expectancy of patients with a durable, continuous-flow left ventricular
  assist device (CF-LVAD) continues to increase. Despite significant improvements
  in the delivery of care for patients with these devices, hemocompatability-related
  adverse events (HRAEs) are still a concern and contribute to significant morbility
  and mortality when they occur. As such, dissemination of current best evidence and
  practices is of critical importance. This ISHLT Consensus Statement is a summative
  ...
disable_comments: true
---
Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative ...